Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency

On this week’s episode, we’re discussing the stresses that practices and clinics face when trying to manage biosimilars as well as some policy considerations that administrators should keep in mind as more biosimilars enter the market and more payers add them to formularies.

I am joined by Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, and a member of The Center for Biosimilars® Advisory Board. She is an expert on the administration and practice perspective of managing biosimilars and has extensive experience supervising a practice that has had to adapt to the growing body of oncology biosimilars that have launched on the US market.

Show notes:

To read more of Kathy’s thoughts on the practice perspective regarding biosimilars, click here.

To learn more about automatic substitution policies, click here.

To learn more about some of the challenges clinicians could face next year as adalimumab biosimilars enter the market, click here.

To learn more about prescription behaviors regarding biosimilars, click here.

To listen to another podcast episode on a tool that can improve infusion center efficiency, click here.